New hope for ovarian cancer: testing a potentially gentler, targeted treatment
NCT ID NCT07285941
Summary
This study is testing a new combination treatment for advanced ovarian cancer. It pairs a standard chemotherapy drug (carboplatin) with a newer, targeted drug called Distamab Vedotin (RC48), which is designed to attack cancer cells with a specific marker (HER2). The goal is to see if this combo can better control the cancer's growth while causing fewer severe side effects than the current standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhe Jiang Cancer Hospital
RECRUITINGZhejiang, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.